Henry Schein (NASDAQ:HSIC) Share Price Passes Above 200-Day Moving Average – Here’s Why

Henry Schein, Inc. (NASDAQ:HSIC) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $70.55 and traded as high as $80.10. Henry Schein shares last traded at $79.98, with a volume of 1,925,410 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HSIC shares. Wells Fargo & Company upped their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Barclays assumed coverage on shares of Henry Schein in a report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. JPMorgan Chase & Co. lifted their price target on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Morgan Stanley boosted their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $76.33.

Henry Schein Trading Up 2.4%

The stock has a market capitalization of $9.42 billion, a PE ratio of 25.31, a PEG ratio of 2.32 and a beta of 0.88. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The business’s 50-day moving average is $75.28 and its two-hundred day moving average is $70.55.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The company had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. raised its stake in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares during the period. Norges Bank purchased a new position in shares of Henry Schein in the second quarter valued at $89,476,000. M.D. Sass LLC acquired a new stake in Henry Schein during the 2nd quarter valued at $79,201,000. Schroder Investment Management Group increased its stake in Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after buying an additional 936,471 shares during the period. Finally, Bank of America Corp DE increased its stake in Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after buying an additional 668,182 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.